"Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial." by Steven M. Opal

Article

Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial.

JAMA (2013)

Steven M. Opal, Brown University
Pierre-Francois Laterre, Université catholique de Louvain
Bruno Francois, Hôpital Dupuytren
Steven P. LaRosa, Scott & White Hospital
Derek C. Angus, University of Pittsburgh
Jean-Paul Mira, University of Paris
Xavier Wittebole, Université catholique de Louvain
Thierry Dugernier, Clinique Saint-Pierre of Ottignies
Dominique Perrotin, François Rabelais University
Mark Tidswell, Tufts University
Luis Jauregui, Mercy Health Partners
Kenneth Krell, Eastern Idaho Regional Med Center
Jan Pachl, Charles University in Prague
Takeshi Takahashi, München Klinik Bogenhausen
Claus Peckelsen, Remington-Davis, Inc.
Edward Cordasco, Remington-Davis, Inc.
Chia-Sheng Chang, China Medical University (Taiwan)
Sandra Oeyen, Ghent University
Naoki Aikawa, Keio University
Tatsuya Maruyama, Keio University
Roland Schein, University of Miami
Andre C. Kalil, University of Nebraska Medical Center
Marc Van Nuffelen, Eisai
Melvyn Lynn, Eisai
Daniel P. Rossignol, Eisai
Jagadish Gogate, Eisai
Mary B. Roberts, Brown University
Mary B. Roberts, Memorial Hospital of Rhode Island
Janice L. Wheeler, Eisai
Jean-Louis Vincent, Université libre de Bruxelles

Link

Disciplines

Publication Date

March 20, 2013

DOI

10.1001/JAMA.2013.2194

Citation Information

Steven M. Opal, Pierre-Francois Laterre, Bruno Francois, Steven P. LaRosa, et al.. "Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial." JAMA Vol. 309 Iss. 11 (2013) p. 1154 - 1162
Available at: http://works.bepress.com/kenneth-krell/7/